Loading
Renal Cell Carcinoma Treatment / Ferroptosis and Cancer Prognosis · Journal article
Journal of Translational Medicine · July 29, 2026
Raises a question worth testing. It does not answer one.
This mechanistic study identifies a previously unrecognized SMYD2–enhancer–DDIT4 regulatory axis in clear cell renal cell carcinoma and demonstrates through molecular, cellular, and murine models that DDIT4 promotes pazopanib resistance via STAT3 pathway activation. The work provides a molecular framework and potential therapeutic target but does not constitute clinical evidence that this axis should be targeted to improve patient outcomes.
Mechanistic study integrating RNA-seq, TCGA analysis, in vitro functional assays, and murine models. Clear cell renal cell carcinoma cell lines, 150 patient samples from ccRCC cohort, and murine ccRCC models. Intervention: SMYD2 knockdown, DDIT4 knockdown, CRISPR-mediated enhancer deletion, pazopanib treatment. Compared with: Control cells and standard pazopanib-resistant cells; SMYD2-intact and DDIT4-intact models as controls.
DDIT4 expression is positively correlated with SMYD2 expression in patient samples and TCGA-KIRC data DDIT4 is highly expressed in renal cell carcinoma and associated with poorer survival outcomes SMYD2 regulates H3K4me1 at a DDIT4 distal enhancer (chr10:72830412–72830891), recruiting transcription factor SPI1 to activate DDIT4 expression
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
While this work identifies a molecular axis associated with pazopanib resistance and survival in ccRCC, it remains preclinical mechanistic evidence. Clinicians should not alter treatment based on this axis alone; prospective validation and clinical trials targeting SMYD2, the enhancer, or DDIT4 are required before therapeutic implications can be established.
This is a mechanistic study identifying a regulatory axis through molecular and cellular assays with supporting murine models, but lacks a prospective clinical trial design, hard clinical endpoints, or validation in independent patient cohorts.
As stated by the source record.
Quoted from the source exactly as published.
While this work identifies a molecular axis associated with pazopanib resistance and survival in ccRCC, it remains preclinical mechanistic evidence. Clinicians should not alter treatment based on this axis alone; prospective validation and clinical trials targeting SMYD2, the enhancer, or DDIT4 are required before therapeutic implications can be established.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
The progression and resistance to targeted therapy, including pazopanib, frequently lead to poor prognosis in clear cell renal cell carcinoma (ccRCC) patients. However, the underlying molecular mechanisms of these processes remain unclear. In this study, we first performed RNA-seq to identify genes that were differentially expressed in both SMYD2-knockdown and pazopanib-resistant cells, indicating their potential role in SMYD2-mediated drug resistance. We analyzed TCGA-KIRC data and 150 patient samples to identify the relationship between SMYD2 and DDIT4 expression levels, as well as the prognostic significance of DDIT4. In vitro functional assays and murine models were applied to evaluate the effects of SMYD2 and DDIT4 on tumor growth and on pazopanib resistance. CUT&Tag and chromosome conformation capture (4 C) assays were applied to identify enhancers associated with SMYD2-mediated regulation of DDIT4, while the JASPAR database was utilized to predict transcription factors involved in the enhancer regulation. CRISPR-mediated enhancer deletion and ChIP–qPCR were subsequently performed to validate the regulatory roles of the identified enhancer and the transcription factor SPI1 in DDIT4 expression. Our study revealed that the expression level of DDIT4 is positively correlated with SMYD2. DDIT4 is highly expressed in renal cell carcinoma and is associated with poorer survival outcomes. Further research revealed that SMYD2 regulates H3K4me1 in a DDIT4 distal enhancer (chr10:72830412–72830891), promoting the recruitment of the transcription factor SPI1, thereby activating DDIT4 expression. We found that DDIT4 promotes the proliferation, metastasis, and pazopanib resistance of ccRCC, and DDIT4 knockdown enhances drug sensitivity in both in vitro and in vivo experiments. Furthermore, the SMYD2–DDIT4 axis activates the downstream STAT3 signaling pathway, thereby promoting tumor progression. In addition, DDIT4-related prognostic features showed potential associations with patient survival and predicted drug sensitivity in computational analyses. Our study identifies a previously unrecognized SMYD2–enhancer–DDIT4 regulatory axis, which promotes tumor progression and pazopanib resistance in ccRCC. These findings may provide potential therapeutic implications to overcome pazopanib resistance and improve treatment outcomes in ccRCC by targeting the SMYD2–enhancer–DDIT4 axis.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.